Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
131.20
+0.48 (+0.37%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults
October 11, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck and Emmy-Nominated Actress Yvonne Orji Unveil Uncovering TNBC, Highlighting the Challenges Faced by Black Women Diagnosed with Triple-Negative Breast Cancer
October 05, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study
October 01, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck to Acquire Acceleron Pharma Inc.
September 30, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Appointment of Thomas H. Glocer as Independent Lead Director
September 29, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck for Mothers: Helping End Maternal Mortality
September 29, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Topics
Death
Exposures
Death
Merck to Hold Third-Quarter 2021 Sales and Earnings Conference Call on October 28
September 28, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib
September 27, 2021
From
Merck & Co., Inc.
Via
Business Wire
LYNPARZA® (olaparib) in Combination With Abiraterone Significantly Delayed Disease Progression in Patients Regardless of Biomarker Status in PROpel Phase 3 Trial in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC)
September 24, 2021
From
Merck & Co., Inc.
Via
Business Wire
Building Sustainable Value for Our Business and Society
September 22, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Exposures
COVID-19
New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space
September 20, 2021
Via
FinancialNewsMedia
Celebrating the Diversity of Our Workforce
September 20, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Exposures
COVID-19
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10)
September 19, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo in the Adjuvant Setting
September 18, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
September 18, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)
September 17, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck To Present New Data From Its Broad Oncology Portfolio and Pipeline at ESMO 2021, Including in Earlier Stages of Cancer
September 08, 2021
From
Merck & Co., Inc.
Via
Business Wire
Improving Medical Care in the Black Community With Family Health Histories
September 08, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Merck to Present at the Morgan Stanley 19th Annual Healthcare Conference
September 07, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy for First-Line Treatment of Patients With Locally Advanced Unresectable or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
September 07, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection
September 01, 2021
From
Merck & Co., Inc.
Via
Business Wire
FDA Approves Updated Indication for Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (Bladder Cancer)
August 31, 2021
From
Merck & Co., Inc.
Via
Business Wire
Employees Help Evacuate Patients From Record Flood in China
August 31, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan
August 26, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Met Key Immunogenicity and Safety Endpoints in Phase 3 Pivotal Trial Evaluating Use in Infants, PNEU-PED (V114-029)
August 25, 2021
From
Merck & Co., Inc.
Via
Business Wire
Leslie A. Brun Resigns from Merck Board of Directors
August 20, 2021
From
Merck & Co., Inc.
Via
Business Wire
New COVID-19 Vaccination Mandates Make Rapid COVID Tests More Essential Than Ever
August 19, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Merck Has Been Named One of the Top Employers in New York by Fortune
August 18, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
FDA Approves Merck’s Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
August 13, 2021
From
Merck & Co., Inc.
Via
Business Wire
FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma (RCC)
August 11, 2021
From
Merck & Co., Inc.
Via
Business Wire
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.